About this trial
Hemato-oncology patients undergoing intensive chemotherapy treatments experience different types of symptoms during and after treatments, which are often refractory to the established therapy. Physical symptoms such as pain, dyspnea, mucositis, insomnia, loss of appetite, constipation and diarrhea, among others, have a huge impact on quality of life, temporarily until symptomatic control, but also permanently with the development of anxiety, depression, long-term fatigue and post-traumatic stress. As recommended by ASCO (American Society of Clinical Oncology), the palliative approach to oncological diseases must be as early as possible and be part of the "standard of care". However, the lack of concrete data on this topic in the last decade served as a barrier to the early integration of this same care for hemato-oncology patients in its various areas. Palliative care presupposes global, interdisciplinary action, carried out by specific teams that must act in situations of incurable or serious illness, in an advanced and progressive phase. The potential benefits can be countless and of significant importance, from the impact on quality of life, symptomatic control, reduction of anxiety and depression and even the promotion of informed and conscious choices at the end of life as well as the reduction of aggressive strategies. used at this stage of the disease.
Eligibility criteria
Qualifiers
Capable of making decisions
Diagnosed with acute myeloid leukemia
Aged 70 years or less
Treated or referred for treatment at the Hematology department of Centro Hospitalar e Universitário de São João.
Disqualifiers
All patients referred for "best supportive care", that is, for supportive care including treatment with cytoreductive intent.
Trial design
Treatments tested in this trial
- Early palliative care integration
Treatment groups
Sponsors and collaborators
Universidade do Porto
Lead sponsor
Centro Hospitalar De São João, E.P.E.
Collaborator